BIO-Europe Spring® 2012 program tackles the cutting edge of industry dealmaking
Keynote to evoke rich history of the Netherlands and the role of partnering in the Dutch biotech sector
Zurich, Switzerland and Amsterdam, The Netherlands – March 5, 2012:
BIO-Europe Spring® 2012 produced by EBD Group, the leading partnering firm for the life science industry, will be held in Amsterdam March 19–21, 2012 at the Amsterdam RAI Convention Center. This year's exciting event will kick off with opening remarks from Eberhard van der Laan, the Mayor of Amsterdam; David Thomas, Director of Industry Research & Analysis for the Biotechnology Industry Organization (BIO); and Carola Schropp, President of EBD Group.
The real flavor of the event will be provided by BIO-Europe Spring keynote speaker Hans Schikan, CEO of Prosensa, a Dutch biopharmaceutical company that targets genetic disorders that have a large unmet medical need, with a primary focus on neuromuscular disorders. Schikan's address, "About polders, pioneers and partnerships," will highlight the thriving Dutch biopharmaceutical sector, and focus on the importance of partnerships as an essential ingredient of success in biopharmaceutical pioneering. In light of the Amsterdam conference setting, Schikan will also explain the role that lowlands and "polders" have played in the Dutch way of cooperation. A polder refers to the Netherlands' characteristic lowlands, or reclaimed farming soil, that are enclosed by embankments known as dikes and that, like windmills, are part of the rich agricultural history of Dutch farm life.
"Multi-stakeholder partnerships with academia, big pharma, other biopharmaceutical companies, healthcare professionals, payers and most importantly with patient organizations are essential to biopharmaceutical innovation," said Schikan. "Prosensa is a great example in this respect: our RNA modulating technology comes originally from our academic partner Leiden University Medical Center. Since our foundation we have worked very closely with patient organizations and in 2009 we established a fruitful collaboration with GlaxoSmithKline for part of our portfolio of personalized medicines for Duchenne Muscular Dystrophy, a rare and severely debilitating neuromuscular disease. Partnerships are embedded in our genes," said Schikan.
The keynote will be followed by a dynamic plenary session entitled, "Are orphan indications the only viable model for future drug development?" The panel will be moderated by Vaughn Kailian of MPM Capital, with panelists Roger Longman of Real Endpoints; Anna Protopapas, Takeda Pharmaceuticals; Hans Schikan of Prosensa; and Philip Vickers, Shire Human Genetic Therapies.
BIO-Europe Spring will also feature other meaningful presentations on the importance of life science partnering, including Monday's panel, "The opportunity of community drug development partnerships for personalized oncology and drug development."
"This panel is really about the future of personalized medicine, and how partnerships form the basis of a new model for transforming cancer drug development," said panel moderator John Freshley of Compendia Bioscience. "We will be examining the feasibility of drug development as a collaboration among research institutions, diagnostic and bio/pharma companies and how to ensure the goals do not exceed the means in delivering cancer drugs to patients that need them. The focus on the delivery of medicine to the patient will continue to drive partnering discussions."
Another panel entitled "Unconventional deals to herculean strategies" will explore multifaceted examples of powerful strategies and non-traditional deals. "Dealmaking used to be more straightforward-perhaps optimizing a portfolio, maybe adding an asset as an insurance policy," said panel moderator Lee McCracken, formerly of Prometheus Laboratories (acquired by Nestlé Health Science). "Now some of the biggest global stakeholders are kicking over the chessboards and upping the stakes with strategies that weave together M&A, partnerships/collaborations, strategic financing, and structured incentives. And by the way, the non-healthcare players are on the rise."
Evening networking events include a welcome reception at De Industrieele Groote Club (IGC) on Sunday, March 18. IGC is a historic business club and society located in the monumental "Industria" building on Dam Square, long the vibrant heart of Amsterdam and the business and cultural center of the Dutch capital. On Monday, March 19, there will be an evening networking reception at Beurs van Berlage, the home of the third Amsterdam Stock Exchange built by H. P. Berlage in 1903. The building is considered to mark the beginning of modern Dutch architecture. Finally, on Tuesday, March 20, there will be another evening networking reception at Muziekgebouw aan 't IJ, the cultural anchor connecting the newly developed IJ banks with the heart of Amsterdam.
Partnering is generated by partneringONE®, the leading conference partnering system for the life sciences. There are thousands of partnering opportunities now ready for your engagement on the system. Information on how to create a partnering profile and begin efficiently identifying and requesting meetings with potential collaborators can be found at
The online registration deadline for the conference is March 16, 2012, 13:00 CET, after which all registrations will be handled on site. Information on the conference and registration details can be found online at http://www.ebdgroup.com/bes/registration/index.php
For more information about BIO-Europe Spring, go to www.ebdgroup.com/bes/index.php.
Additional links and information:
Follow BIO-Europe Spring 2012 on Twitter: twitter.com/EBDgroup (hashtag: #BES12)
LinkedIn Event site: http://linkd.in/uA0L0x
About EBD Group
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group's partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.
EBD Group's conferences are run with the support of leading corporations and international trade associations and include:
- BIO-Europe® and BIO-Europe Spring®, Europe's largest life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
- BioPharm America™, the fastest growing partnering event in North America
- Biotech Showcase™, a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors
- BioEquity Europe, the investor conference co-organized with BioCentury Publications and BIO
- ChinaBio® Partnering Forum, the first dedicated biotech/pharma partnering conference in China, co-produced with ChinaBio® LLC
- EuroMedtech™, EBD Group's partnering event for the innovative medical technology industry
- Partnering for Global Impact®, a new partnering conference providing an innovative forum to partner, identify and generate social and philanthropic investment and funding opportunities
EBD Group's sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year.
Outside of the conference format, EBD Group's consultants provide hands-on assistance for firms seeking to in- or out-license products and technologies.
EBD Group has offices in the USA and Europe.
Additional links and information:
Follow EBD Group on Twitter: twitter.com/ebdgroup
For more information please visit www.ebdgroup.com.